Cargando…

VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease

Cannabinoids have shown to exert neuroprotective actions in animal models by acting at different targets including canonical cannabinoid receptors and PPARγ. We previously showed that VCE-003, a cannabigerol (CBG) quinone derivative, is a novel neuroprotective and anti-inflammatory cannabinoid actin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz-Alonso, Javier, Paraíso-Luna, Juan, Navarrete, Carmen, del Río, Carmen, Cantarero, Irene, Palomares, Belén, Aguareles, José, Fernández-Ruiz, Javier, Bellido, María Luz, Pollastro, Federica, Appendino, Giovanni, Calzado, Marco A., Galve-Roperh, Ismael, Muñoz, Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949444/ https://www.ncbi.nlm.nih.gov/pubmed/27430371 http://dx.doi.org/10.1038/srep29789

Ejemplares similares

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
por: Aguareles, José, et al.
Publicado: (2019)

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
por: Rodríguez-Carreiro, Santiago, et al.
Publicado: (2023)

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
por: García, Concepción, et al.
Publicado: (2018)

Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2019)

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
por: del Río, Carmen, et al.
Publicado: (2016)

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy
por: Navarrete, Carmen, et al.
Publicado: (2018)

VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity
por: Palomares, Belen, et al.
Publicado: (2018)

A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
por: Carrillo-Salinas, Francisco J., et al.
Publicado: (2014)

In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
por: Gugliandolo, Agnese, et al.
Publicado: (2018)

Biosynthesis of cannabigerol and cannabigerolic acid: the gateways to further cannabinoid production
por: Kearsey, Lewis J, et al.
Publicado: (2023)

Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol
por: Mammana, Santa, et al.
Publicado: (2019)

Cannabigerol Activates Cytoskeletal Remodeling via Wnt/PCP in NSC-34: An In Vitro Transcriptional Study
por: Anchesi, Ivan, et al.
Publicado: (2023)

Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia
por: García-Rincón, Daniel, et al.
Publicado: (2019)

The Origin and Biomedical Relevance of Cannabigerol
por: Jastrząb, Anna, et al.
Publicado: (2022)

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
por: Calapai, Fabrizio, et al.
Publicado: (2022)

Will Cannabigerol Trigger Neuroregeneration after a Spinal Cord Injury? An In Vitro Answer from NSC-34 Scratch-Injured Cells Transcriptome
por: Valeri, Andrea, et al.
Publicado: (2022)

The Transcriptomic Analysis of NSC-34 Motor Neuron-Like Cells Reveals That Cannabigerol Influences Synaptic Pathways: A Comparative Study with Cannabidiol
por: Gugliandolo, Agnese, et al.
Publicado: (2020)

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
por: Burgaz, Sonia, et al.
Publicado: (2021)

Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure
por: de Salas-Quiroga, Adán, et al.
Publicado: (2020)

Stochastic Modeling of Smartphones GNSS Observations Using LS-VCE and Application to Samsung S20
por: Zangenehnejad, Farzaneh, et al.
Publicado: (2023)

0032. Relationship between microcirculatory alterations and venous-to-arterial carbon dioxide differences in patients with septic shock
por: Ospina-Tascón, GA, et al.
Publicado: (2014)

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2021)

Anti-Biofilm Activity of Cannabigerol against Streptococcus mutans
por: Aqawi, Muna, et al.
Publicado: (2021)

Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans
por: Aqawi, Muna, et al.
Publicado: (2021)

Acute Cannabigerol Administration Lowers Blood Pressure in Mice
por: Vernail, Victoria L., et al.
Publicado: (2022)

EHMTI-0032. Persistence and switching characteristics among chronic migraine patient population: a retrospective claims analysis
por: Hepp, Z, et al.
Publicado: (2014)

Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi
por: Aqawi, Muna, et al.
Publicado: (2020)

Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain
por: Nachnani, Rahul, et al.
Publicado: (2023)

Anaplasma phagocytophilum APH0032 Is Exposed on the Cytosolic Face of the Pathogen-Occupied Vacuole and Co-opts Host Cell SUMOylation
por: Oki, Aminat T., et al.
Publicado: (2016)

Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol
por: Brierley, Daniel I., et al.
Publicado: (2019)

Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota
por: Luz-Veiga, Mariana, et al.
Publicado: (2023)

Mannich-type modifications of (−)-cannabidiol and (−)-cannabigerol leading to new, bioactive derivatives
por: Lőrincz, Eszter Boglárka, et al.
Publicado: (2023)

A31 OUTCOMES OF PATIENTS UNDERGOING REPEAT VIDEOCAPSULE ENDOSCOPY (VCE) PRESENTING WITH OBSCURE GASTROINTESTINAL BLEEDING (OGIB)
por: Krahn, T, et al.
Publicado: (2022)

Where are the students? A close reading of priorities and silences in scholarly and public debates on VCE English (1990–2021)
por: Horton, Allayne, et al.
Publicado: (2022)

Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats
por: Brierley, Daniel I, et al.
Publicado: (2016)

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
por: Lah, Tamara T., et al.
Publicado: (2021)

Cannabidiol and Cannabigerol Modify the Composition and Physicochemical Properties of Keratinocyte Membranes Exposed to UVA
por: Wroński, Adam, et al.
Publicado: (2023)

Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis
por: Le Stunff, Hervé, et al.
Publicado: (2002)

Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link?
por: Fogaça, Manoela Viar, et al.
Publicado: (2013)

VceC Mediated IRE1 Pathway and Inhibited CHOP-induced Apoptosis to Support Brucella Replication in Goat Trophoblast Cells
por: Zhi, Feijie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gooo6k0f8nmv54umvg9nk1vh3k